Maine Cancer Foundation has announced a recent funding award of $375,000 to foster the development of a commercially available early test for estrogen negative breast cancer. Dr. Srinidi Mohan, an assistant professor in the University of New England College of Pharmacy has received a provisional patent for his early detection and disease monitoring method, which uses a marker in the blood to detect the presence of highly aggressive tumors and to help track cancer growth.
This groundbreaking work aligns with MCF’s mission of reducing incidence and mortality of cancer throughout Maine.
To hear more, check out this month’s Challenge Cancer 2020 package from our partners at WMTW-WV as they interview Dr. Mohan and our own Program Director, Aysha Sheikh.